Compound preparation for treating IgA nephropathy
A compound preparation and kidney disease technology, which is applied in the field of kidney disease treatment, can solve the problems of unsatisfactory curative effect, inability to completely prevent ESRD histological changes, inability to reduce urine protein to the normal range, etc., and achieve the effect of small side effects, good treatment and significant curative effect
Inactive Publication Date: 2014-04-16
GUANGDONG GENERAL HOSPITAL
View PDF0 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
In view of the important role of Ang Ⅱ in the pathogenesis of IgA nephropathy, the use of ARB, a drug that blocks RAS activity, in the treatment of IgA nephropathy has been proven to be effective, but its clinical efficacy is not satisfactory, even combined with angiotensin converting enzyme inhibitor (ACEI) And ARB, can not reduce the urinary protein to the normal range, and can not completely prevent the occurrence of ESRD and improve the histological changes of the kidney, suggesting that simply blocking the activation of the RAS system is not enough in the treatment of IgA nephropathy
The use of antioxidants alone in the treatment of IgA nephropathy, although blocking the oxidative stress injury mechanism in the pathogenesis of IgA nephropathy, does not block the activation of the RAS system, and its curative effect is not satisfactory.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment Construction
[0016] 1. Case selection criteria:
[0017] a. Renal biopsy pathologically and clinically confirmed patients with IgA nephropathy;
[0018] b. Age 18-60 years old;
[0019] c. Urinary protein excretion of 1.0-2.5g / day was confirmed by at least 3 tests, and the cause of urinary tract infection or congestive heart failure (NYHA grade 3-4 of the New York Heart Association) was excluded;
[0020] d. Serum creatinine level <265.2umol / L, and the fluctuation range in the first 3 months is less than 30%;
[0021] e. Did not take ACEI, ARB, antioxidants and lipid-lowering drugs for at least 6 weeks before enrollment, and did not take hormones and cytotoxic drugs for at least 1 year before enrollment.
[0022] 2. Case exclusion criteria:
[0023] a. Secondary IgA nephropathy: systemic diseases such as allergic purpura nephritis, viral hepatitis, liver cirrhosis, systemic lupus erythematosus and connective tissue diseases;
[0024] b. Malignant hypertension or acute renal failure;
...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The invention discloses a compound preparation for treating IgA nephropathy. The compound preparation for treating the IgA nephropathy consists of the following components in parts by weight: 5-15 parts of sartan medicine and 50 parts of probucol. The compound preparation is obvious in curative effect on slight proteinuria IgA nephropathy, moderate proteinuria IgA nephropathy and severe proteinuria IgA nephropathy. Shown by experimental results, the compound preparation is superior to single reagents, can be used for treating the IgA nephropathy better and is small in side effect.
Description
technical field [0001] The technical field of nephropathy treatment of the present invention, in particular, relates to a compound preparation for treating IgA nephropathy. Background technique [0002] IgA nephropathy is the most common primary glomerular disease, accounting for about 30-40% of the primary glomerular diseases in my country. Among patients diagnosed with IgA nephropathy, about 20% of patients develop to In the stage of end-stage renal disease (ESRD), IgA nephropathy has become the first primary cause of chronic maintenance hemodialysis patients in my country. Therefore, it is of great significance to improve the therapeutic effect of patients with IgA nephropathy as much as possible and delay the progressive deterioration of renal function in patients with IgA nephropathy to reduce the occurrence of ESRD. [0003] Currently, there is no specific drug treatment for IgA nephropathy, nor is there a recognized treatment guideline. The main goals of treatment ar...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4184A61K31/4178A61K31/41A61K31/10A61P13/12
Inventor 史伟叶智明刘双信梁馨苓梁永正章斌王文健马建超夏运风徐丽霞冯仲林李志莲
Owner GUANGDONG GENERAL HOSPITAL